

DAFTAR PUSTAKA

1. Atmakusuma D & Setyaningsih I.2009. *Dasar-dasar thalassemia: salah satu jenis hemoglobinopati*. Jakarta: Interna Publishing.. hal. 44-48.
2. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, Karagiorga M. 2005.*Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia*. Chest,127:1523-1530.
3. Depkes RI. 2018. *Keputusan Menteri Kesehatan Republik Indonesia nomor hk.01.07/menkes/1/2018 tentang Pedoman Nasional Pelayanan Kedokteran Tatalaksana Thalassemia..* hal. 4-8.
4. Taher AT, Otrrock ZK, Uthman I, Cappellini MD.2008. *Thalassemia and hypercoagulability*. Blood Rev, 22:283-292.
5. Thalassemia International Federation: *Guidelines for the clinical management of thalassemia 2nd edition*. 2008. Diakses dari [http:// www.thalassemia.org.cy](http://www.thalassemia.org.cy) pada bulan September 2018.
6. Borgna-Pignatti C, Galanello R: *Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis*. 2004. In Wintrobe's Clinical Hematology Volume 42. 11th edition. Lippincott Williams & Wilkins. Philadelphia,;:1319-1365.
7. Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P,Maggio A, Renda D, Lai ME, Mandas A, Forni G, Piga A, Bisconte MG.2004. *Hepatocellular carcinoma in the thalassemia syndromes*. Br J Haematol, 124:114-117.
8. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL,Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A.2005:*Survival and complications in thalassemia*. Ann N Y Acad Sci,1054:40-47.
9. Rachmilewitz EA, Giardina PJ.2011.*How I treat thalassemia*. Blood. Sep 29. 118(13):3479-88.
10. Jacob HS, Winterhalter KH. 1970. *The role of hemoglobin heme loss in Heinz body formation: studies with a partially heme-deficient hemoglobin and with genetically unstable hemoglobins*. J Clin Invest. Nov. 49 (11):2008-16.
11. Hapgood G, Walsh T, Cukierman R, Paul E, Cheng K, Bowden DK. 2015. *Erythropoiesis is not equally suppressed in transfused males and females with β -thalassemia major: are there clinical implications?*. Haematologica. Aug. 100 (8):e292-4.

12. Lucarelli G, Galimberti M, Polchi P.1993.*Marrow transplantation in patients with thalassemia responsive to iron chelation therapy*. N Engl J Med. Sep 16. 329(12):840-4.
13. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR.2004.: *Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America*. Blood, 104:34-39.
14. Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, Young NS, Allen CJ, Farrell DE, Harris JW.1993. *Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major*. Am J Hematol, 42:81-85.
15. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G .2000. *Hepatic iron concentration and total body iron stores in thalassemia major*. N Engl J Med,343:327-331.
16. La Nasa G, Argiolu F, Giardini C, Pession A, Fagioli F, Caocci G, Vacca A, DeStefano P, Piras E, Ledda A, Piroddi A, Littera R, Nesci S, Locatelli F. 2005.*Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group*. Ann N Y Acad Sci, 1054:186-195.
17. Forget, B., G. Cannelos, and N. Berlin,2010. eds. *Pediatric Clinics of North America*. Thalassemia. Volume 24, Number 6. W.B. Saunders Company,.
18. Demir AD, Kacan A, Nursoy MA, et al.2014.*Hematological Indices for Differential Diagnosis of Beta Thalassemia Trait and Iron Deficiency Anemia*. Hindawi.. hal. 1-7.
19. Cappellini MD, Taher .2008.A: *Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload*. Expert Opin Pharmacother, 9:2391-2402.
20. Prati D. 2000. *Benefits and complications of regular blood transfusion in patients with β -thalassaemia major*. Vox Sang; 79:129-37.
21. Angelucci E, Brittenham GM, Christine E, et al . 2000. *Hepatic iron concentration and total body iron stores in thalassemia major*. N Engl J Med;343:327-31
22. Dietrich CF, Serra C, Jedrzejczyk M. 2012. *Ultrasound of the liver*.EFSUMB – European Course Book.. hal. 4-7.
23. Hirche TO, Ignee A, Hirche H, Schneider A, Dietrich CF. 2007. *Evaluation of hepatic steatosis by ultrasound in patients with chronic hepatitis C virus infection*. Liver Int; 27(6):748-757.
24. Couinaud C. *The parabiliary venous system*. Surg Radiol Anat 1988; 10(4):311-316.

25. Papanicolaou A, Gourtsoyiannis NC.1989.*Abdomina Ultrasound in β -Thalassemia*. Dalam Radiology of Thalassemia. Springer. hal. 86-88.
26. Taufiqurrahman, M .2008. *Pengantar Metodologi Penelitian untuk Ilmu Kesehatan*. Surakarta : UNS Press.. Hal 50-54
27. Ghozali, I. dan Castellan. Statistik Non-Parametrik: Badan Penerbit UNDIP. 2002. hal. 33-36.
28. Thomas Benter, MD, Lothar Klühs, MD, Ulf Teichgräber, MD, MBA. *Sonography of the Spleen. Department of Radiology, CharitéUniversity Hospital, Charitéplatz 1, D-10117Berlin, Germany*.
29. Murti B. *Desain dan ukuran sampel dalam penelitian kesehatan*. Edisi ke 2. Yogyakarta : (2010)Gadjah Mada University Press
30. Elmore Susan A. 2006. *Enhanced Histopathology of the Spleen..* Laboratory of Experimental Pathology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA
31. Yunfu, Wan Yee Lau. 2016. *Hypersplenism: History and current status (Review)*. Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, P.R. China
32. Widoyoko SEP. *Teknik Penyusunan Instrumen Penelitian*. Yogyakarta : (2012)Pustaka Belajar.
33. Siegel, J Marilyn. 2011. *Pediatric Sonography*. Lippincott Williams & Wilkins, Wolters Kluwer Philadelphia, USA
34. Robben Simon, Rijn van Rick, Smithuis Robin. 2018. *Normal Value Ultrasound*. <http://www.radiologyassistant.nl/en/p5a3056eebe646/normal-values-ultrasound.htm>
| diakses pada hari Senin, 18 Febuari 2019. pukul 01.26
35. Papakonstabinou Olympia, Drakonaki Eleni, *et al*. 2015. *MR Imaging of Spleen in Beta-Thalassemia Major*. Departement Radiology of Atticon Hospital, Athens 12464, Greece.
36. Cappellini MD, Cohen A, Porter J, *et al*. 2014. *Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) [Internet]. 3rd edition; Nicosia (CY): Thalassaemia International Federation;*
37. Regina Bayley. 2018. *Spleen Anatomy*. <https://www.thoughtco.com/spleen-anatomy-373248>. Diakses pada hari Minggu, 24 febuari 2018 pukul 21.00

38. Papavasiliou Th C, Ph. Fessas Cambouris (Eds.) *Radiology of Thalassemia*. Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Hong Kong
39. Pootrakul P, Vongsmassa V. 1984. *Serrum Ferritin Level in Thalassemias and The Effect of Splenectomy*. Departement of Clinical Microscopy and Radiological Technology, Medicine Departemen Siriraj Hospital, Mahidol University, Thailand
40. Mary Ann Knovich, Jonathan A. Storey, Lan G. Coffman, and Suzy V. Torti Frank M. Torti. 2009. *Ferritin for the Clinician*. Section on Hematology and Oncology, Wake Forest University Health Sciences, Medical Center, Boulevard, Winston-Salem, NC 27157-1082, USA, 336-716-7973, phone 336-716-5687 fax
41. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, Karagiorga M. 2005. *Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia*. *Chest*, 127:1523-1530.
42. Weatherall DJ, Clegg JB. 2001. *The Thalassemia Syndromes*. Oxford: Blackwell Science.
43. Taher A, Tyan PI, Cappellini MD. 2014. *Guidelines for the management of transfusion dependent thalassaemia (TMD)*. Thalassaemia International Federation. Bab 6. The Spleen.
44. Rosenberg HK, Markowitz RI, Kolberg H, Park C, Hubbard A, Bellah RD. 1991. *Normal splenic size in infants and children: sonographic measurement*. *AJR*; 157: 119-21.
45. Karimi M, et al. 2009. *Prevalence of hepatosplenomegaly in beta thalassemia minor subjects in Iran*. *European Journal of Radiology*; 69: 120-2.
46. Thalassaemia International Federation: *Guidelines for the clinical management of thalassaemia 2nd edition*. 2008. Diakses dari [http:// www.thalassaemia. org.cy](http://www.thalassaemia.org.cy) pada bulan September 2018.
47. Mishra AK, Tiwari A. 2013. *Iron overload in beta thalassaemia major intermedia patients*. *Maedica*; 8(4): 328-32.
48. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. 2010. *Serum ferritin: past, present and future*. *Biochimica et Biophysica Acta*; 1800(8): 760–9
49. Pootrakul P, Vongsmassa V. 1984. *Serrum Ferritin Level in Thalassemias and The Effect of Splenectomy*. *Acta Haematologica*; 66(4): 244-50.
50. University of Rochester Medical Center. *Ferritin (Blood)*. Cited from https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=167&contentid=ferritin_blood. At Sept 6, 2019 21.00.

51. Riaz H, *et al.* 2011. *Serum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan.* BMC Research Notes: 287.
52. Rezaie HM, *et al.* 2018. *Comparison of spleen, liver, and kidney volume and span using multiplanar CT-Scan vs. ultrasonography in 1-12 year-old patients.* Advances in Bioscience and Clinical Medicine; 7(1): 36-40.
53. Elstein D, *et al.* 1997. *Liver and spleen size in gaucher disease.* J Ultrasound; 16: 209-11.
54. Cavill I. 1999. *Iron status as measured by serum ferritin: the marker and its limitation.* American Journal of Kidney Disease; 34(4): 12-17.
55. Muhammad A, Sianipar O. 2005. *Penentuan defisiensi besi anemia penyakit kronis menggunakan peran indeks sTFR-F.* Indonesian Journal of Clinical Pathology and Medical laboratory; 12(1): 9-15.
56. Greenland S, *et al.* 2016. *Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations.* Eur J Epidemiol; 31: 337-50.
57. Aydinok Y, *et al.* 2018. *A National Registry of Thalassemia in Turkey: Demographic and Disease Characteristics of Patients, Achievements, and Challenges in Prevention.* Turk J Haematol;35(1):12-18.